Roy Baynes, MD, PhD
The China National Drug Administration has approved pembrolizumab (Keytruda) for the treatment of adult patients with unresectable or metastatic melanoma after 1 prior line of therapy, according to Merck (MSD) the manufacturer of the PD-1 inhibitor.
<.001). The complete response rates were 12%, 13%, and 5%, respectively.
Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet Oncol. 2017;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X.
... to read the full story